Parkinson's Disease Drugs Market by Drug Class (Decarboxylase Inhibitors, Dopamine Agonists, COMT Inhibitors, MAO-B Inhibitors, Others), by Route of Administration (Oral, Injection, Transdermal), by Age Group (50 or below 50, Above 50 years): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global Parkinson’s disease drugs market was valued at $5,689.12 million in 2021, and is projected to reach $10,402.65 million by 2031, registering a CAGR of 6.2% from 2021 to 2031.
Parkinson's disease is a slowly progressing neurological condition that affects a few specific nerve cells (neurons) in the substantia nigra region of the brain. These cells produce dopamine, a chemical that transmits the signal in brain. Dopamine is essential for controlling body moves and cause of many Parkinson's disease symptoms is a decrease in dopamine level. People over the age of 50 are mostly affected by Parkinson’s disease. They may further experience mental & behavioral changes, sleep problems, depression, memory difficulties, and fatigue. The Parkinson’s disease drugs are used to treat Parkinson’s disease and reduces the symptoms of Parkinson’s disease. Signs and symptoms of Parkinson’s disease such as tremor, bradykinesia, rigid muscles, impaired posture and balance. Many of the symptoms are due to loss of neurons. The major risk factor is the age and others factors such as environmental factors, heredity, sex, exposure to toxins.
The major key factor such as increase in demand for Parkinson’s disease drugs is anticipated to increase globally during the forecast period, owing to rise in geriatric population and rising prevalence rate of Parkinson’s disease patients. Moreover, an increase in investments by key players toward R&D related to Parkinson’s disease drugs further drive growth of the market globally. However, adverse events associated with therapeutics of Parkinson’s disease drugs and high cost of treatment associated with Parkinson’s disease may limit the market growth. Conversely, high growth potential in untapped emerging countries and increasing R&D and continuous drug approval and product launch of Parkinson’s disease drugs are expected to offer lucrative growth opportunities for the key player in the market.
The Parkinson’s disease drugs market is segmented on the basis of drug class, route of administration, age group and region. On the basis of drug class, the market is classified into decarboxylase inhibitors, dopamine agonists, COMT inhibitors, MAO-B inhibitors and others. On the basis of route of administration, it is segmented into oral, injection and transdermal. On the basis of age group, it is segmented into 50 or below 50 and above 50 years. Furthermore, on the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include AbbVie Inc., Amneal Pharmaceuticals Inc Cantata Bio, Biogen Inc., C.H. Boehringer Sohn Ko.KG, Eli Lilly company, Glaxosmithkline Plc, Gentech Healthcare, Intas Pharmaceuticals Limited, Orion Corporation, Novartis AG, Pfizer Inc., Square group, Sun Pharmaceutical Industries Limited, Teva Pharmaceuticals, Torrent Group, UCB pharma, Viatris Inc.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global spatial genomics and transcriptomics market along with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry helps to understand the application and products of spatial genomics and transcriptomics used across the globe.
Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
Key Market Segments
By Drug Class
* Decarboxylase Inhibitors
* Distribution Channel
* Hospital Pharmacies
* Drug stores and Retail Pharmacies
* Online Providers
* Dopamine Agonists
* COMT Inhibitors
* MAO-B Inhibitors
* Others
Route of Administration
* Oral
* Injection
* Transdermal
By Age Group
* 50 or below 50
* Above 50 years
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Decarboxylase Inhibitors
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.2.4 Decarboxylase Inhibitors Parkinson's Disease Drugs Market by Distribution Channel
- 4.2.4.1 Hospital Pharmacies Market size and forecast, by region
- 4.2.4.2 Drug stores and Retail Pharmacies Market size and forecast, by region
- 4.2.4.3 Online Providers Market size and forecast, by region
- 4.3 Dopamine Agonists
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 COMT Inhibitors
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 MAO-B Inhibitors
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- 4.6 Others
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market analysis by country
- CHAPTER 5: PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Oral
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Injection
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Transdermal
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- CHAPTER 6: PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 50 or below 50
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Above 50 years
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- CHAPTER 7: PARKINSON'S DISEASE DRUGS MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Drug Class
- 7.2.2.1 North America Decarboxylase Inhibitors Parkinson's Disease Drugs Market by Distribution Channel
- 7.2.3 North America Market size and forecast, by Route of Administration
- 7.2.4 North America Market size and forecast, by Age Group
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Drug Class
- 7.2.5.1.2 Market size and forecast, by Route of Administration
- 7.2.5.1.3 Market size and forecast, by Age Group
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Drug Class
- 7.2.5.2.2 Market size and forecast, by Route of Administration
- 7.2.5.2.3 Market size and forecast, by Age Group
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Drug Class
- 7.2.5.3.2 Market size and forecast, by Route of Administration
- 7.2.5.3.3 Market size and forecast, by Age Group
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Drug Class
- 7.3.2.1 Europe Decarboxylase Inhibitors Parkinson's Disease Drugs Market by Distribution Channel
- 7.3.3 Europe Market size and forecast, by Route of Administration
- 7.3.4 Europe Market size and forecast, by Age Group
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Drug Class
- 7.3.5.1.2 Market size and forecast, by Route of Administration
- 7.3.5.1.3 Market size and forecast, by Age Group
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Drug Class
- 7.3.5.2.2 Market size and forecast, by Route of Administration
- 7.3.5.2.3 Market size and forecast, by Age Group
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Drug Class
- 7.3.5.3.2 Market size and forecast, by Route of Administration
- 7.3.5.3.3 Market size and forecast, by Age Group
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Drug Class
- 7.3.5.4.2 Market size and forecast, by Route of Administration
- 7.3.5.4.3 Market size and forecast, by Age Group
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Drug Class
- 7.3.5.5.2 Market size and forecast, by Route of Administration
- 7.3.5.5.3 Market size and forecast, by Age Group
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Drug Class
- 7.3.5.6.2 Market size and forecast, by Route of Administration
- 7.3.5.6.3 Market size and forecast, by Age Group
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Drug Class
- 7.4.2.1 Asia-Pacific Decarboxylase Inhibitors Parkinson's Disease Drugs Market by Distribution Channel
- 7.4.3 Asia-Pacific Market size and forecast, by Route of Administration
- 7.4.4 Asia-Pacific Market size and forecast, by Age Group
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Drug Class
- 7.4.5.1.2 Market size and forecast, by Route of Administration
- 7.4.5.1.3 Market size and forecast, by Age Group
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Drug Class
- 7.4.5.2.2 Market size and forecast, by Route of Administration
- 7.4.5.2.3 Market size and forecast, by Age Group
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by Drug Class
- 7.4.5.3.2 Market size and forecast, by Route of Administration
- 7.4.5.3.3 Market size and forecast, by Age Group
- 7.4.5.4 Australia
- 7.4.5.4.1 Market size and forecast, by Drug Class
- 7.4.5.4.2 Market size and forecast, by Route of Administration
- 7.4.5.4.3 Market size and forecast, by Age Group
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Drug Class
- 7.4.5.5.2 Market size and forecast, by Route of Administration
- 7.4.5.5.3 Market size and forecast, by Age Group
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Drug Class
- 7.4.5.6.2 Market size and forecast, by Route of Administration
- 7.4.5.6.3 Market size and forecast, by Age Group
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Drug Class
- 7.5.2.1 LAMEA Decarboxylase Inhibitors Parkinson's Disease Drugs Market by Distribution Channel
- 7.5.3 LAMEA Market size and forecast, by Route of Administration
- 7.5.4 LAMEA Market size and forecast, by Age Group
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Drug Class
- 7.5.5.1.2 Market size and forecast, by Route of Administration
- 7.5.5.1.3 Market size and forecast, by Age Group
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Drug Class
- 7.5.5.2.2 Market size and forecast, by Route of Administration
- 7.5.5.2.3 Market size and forecast, by Age Group
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Drug Class
- 7.5.5.3.2 Market size and forecast, by Route of Administration
- 7.5.5.3.3 Market size and forecast, by Age Group
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Drug Class
- 7.5.5.4.2 Market size and forecast, by Route of Administration
- 7.5.5.4.3 Market size and forecast, by Age Group
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 AbbVie Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Amneal Pharmaceuticals, Inc.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Biogen Inc.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 C.H. Boehringer Sohn Ko. KG
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Eli Lilly and Company
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Gentech Healthcare
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 GlaxoSmithKline Plc
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Intas Pharmaceuticals Limited
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Novartis AG
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Orion Corporation
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- 9.11 Pfizer Inc.
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
- 9.12 Square group
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
- 9.13 Sun Pharmaceutical Industries
- 9.13.1 Company overview
- 9.13.2 Company snapshot
- 9.13.3 Operating business segments
- 9.13.4 Product portfolio
- 9.13.5 Business performance
- 9.13.6 Key strategic moves and developments
- 9.14 Teva Pharmaceuticals
- 9.14.1 Company overview
- 9.14.2 Company snapshot
- 9.14.3 Operating business segments
- 9.14.4 Product portfolio
- 9.14.5 Business performance
- 9.14.6 Key strategic moves and developments
- 9.15 Torrent Group
- 9.15.1 Company overview
- 9.15.2 Company snapshot
- 9.15.3 Operating business segments
- 9.15.4 Product portfolio
- 9.15.5 Business performance
- 9.15.6 Key strategic moves and developments
- 9.16 UCB
- 9.16.1 Company overview
- 9.16.2 Company snapshot
- 9.16.3 Operating business segments
- 9.16.4 Product portfolio
- 9.16.5 Business performance
- 9.16.6 Key strategic moves and developments
- 9.17 Viatris Inc.
- 9.17.1 Company overview
- 9.17.2 Company snapshot
- 9.17.3 Operating business segments
- 9.17.4 Product portfolio
- 9.17.5 Business performance
- 9.17.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 2. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR DECARBOXYLASE INHIBITORS, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. PARKINSON'S DISEASE DRUGS MARKET FOR DECARBOXYLASE INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. GLOBAL DECARBOXYLASE INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 5. PARKINSON'S DISEASE DRUGS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 6. PARKINSON'S DISEASE DRUGS MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 7. PARKINSON'S DISEASE DRUGS MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 8. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR DOPAMINE AGONISTS, BY REGION, 2021-2031 ($MILLION)
- TABLE 9. PARKINSON'S DISEASE DRUGS MARKET FOR DOPAMINE AGONISTS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 10. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR COMT INHIBITORS, BY REGION, 2021-2031 ($MILLION)
- TABLE 11. PARKINSON'S DISEASE DRUGS MARKET FOR COMT INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 12. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR MAO-B INHIBITORS, BY REGION, 2021-2031 ($MILLION)
- TABLE 13. PARKINSON'S DISEASE DRUGS MARKET FOR MAO-B INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 14. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 15. PARKINSON'S DISEASE DRUGS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 16. GLOBAL PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 17. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
- TABLE 18. PARKINSON'S DISEASE DRUGS MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 19. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR INJECTION, BY REGION, 2021-2031 ($MILLION)
- TABLE 20. PARKINSON'S DISEASE DRUGS MARKET FOR INJECTION, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 21. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR TRANSDERMAL, BY REGION, 2021-2031 ($MILLION)
- TABLE 22. PARKINSON'S DISEASE DRUGS MARKET FOR TRANSDERMAL, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 23. GLOBAL PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 24. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR 50 OR BELOW 50, BY REGION, 2021-2031 ($MILLION)
- TABLE 25. PARKINSON'S DISEASE DRUGS MARKET FOR 50 OR BELOW 50, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 26. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR ABOVE 50 YEARS, BY REGION, 2021-2031 ($MILLION)
- TABLE 27. PARKINSON'S DISEASE DRUGS MARKET FOR ABOVE 50 YEARS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 28. PARKINSON'S DISEASE DRUGS MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 29. NORTH AMERICA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 30. NORTH AMERICA DECARBOXYLASE INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 31. NORTH AMERICA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 32. NORTH AMERICA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 33. NORTH AMERICA PARKINSON'S DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 34. U.S. PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 35. U.S. PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 36. U.S. PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 37. CANADA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 38. CANADA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 39. CANADA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 40. MEXICO PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 41. MEXICO PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 42. MEXICO PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 43. EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 44. EUROPE DECARBOXYLASE INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 45. EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 46. EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 47. EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 48. GERMANY PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 49. GERMANY PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 50. GERMANY PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 51. FRANCE PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 52. FRANCE PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 53. FRANCE PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 54. UK PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 55. UK PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 56. UK PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 57. ITALY PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 58. ITALY PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 59. ITALY PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 60. SPAIN PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 61. SPAIN PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 62. SPAIN PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 63. REST OF EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 64. REST OF EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 65. REST OF EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 66. ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 67. ASIA-PACIFIC DECARBOXYLASE INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 68. ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 69. ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 70. ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 71. JAPAN PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 72. JAPAN PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 73. JAPAN PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 74. CHINA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 75. CHINA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 76. CHINA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 77. INDIA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 78. INDIA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 79. INDIA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 80. AUSTRALIA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 81. AUSTRALIA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 82. AUSTRALIA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 83. SOUTH KOREA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 84. SOUTH KOREA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 85. SOUTH KOREA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 86. REST OF ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 87. REST OF ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 88. REST OF ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 89. LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 90. LAMEA DECARBOXYLASE INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 91. LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 92. LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 93. LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 94. BRAZIL PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 95. BRAZIL PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 96. BRAZIL PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 97. SAUDI ARABIA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 98. SAUDI ARABIA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 99. SAUDI ARABIA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 100. SOUTH AFRICA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 101. SOUTH AFRICA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 102. SOUTH AFRICA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 103. REST OF LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 104. REST OF LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
- TABLE 105. REST OF LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
- TABLE 106.ABBVIE INC.: COMPANY SNAPSHOT
- TABLE 107.ABBVIE INC.: OPERATING SEGMENTS
- TABLE 108.ABBVIE INC.: PRODUCT PORTFOLIO
- TABLE 109.ABBVIE INC.: NET SALES,
- TABLE 110.ABBVIE INC.: KEY STRATERGIES
- TABLE 111.AMNEAL PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
- TABLE 112.AMNEAL PHARMACEUTICALS, INC.: OPERATING SEGMENTS
- TABLE 113.AMNEAL PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
- TABLE 114.AMNEAL PHARMACEUTICALS, INC.: NET SALES,
- TABLE 115.AMNEAL PHARMACEUTICALS, INC.: KEY STRATERGIES
- TABLE 116.BIOGEN INC.: COMPANY SNAPSHOT
- TABLE 117.BIOGEN INC.: OPERATING SEGMENTS
- TABLE 118.BIOGEN INC.: PRODUCT PORTFOLIO
- TABLE 119.BIOGEN INC.: NET SALES,
- TABLE 120.BIOGEN INC.: KEY STRATERGIES
- TABLE 121.C.H. BOEHRINGER SOHN KO. KG: COMPANY SNAPSHOT
- TABLE 122.C.H. BOEHRINGER SOHN KO. KG: OPERATING SEGMENTS
- TABLE 123.C.H. BOEHRINGER SOHN KO. KG: PRODUCT PORTFOLIO
- TABLE 124.C.H. BOEHRINGER SOHN KO. KG: NET SALES,
- TABLE 125.C.H. BOEHRINGER SOHN KO. KG: KEY STRATERGIES
- TABLE 126.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
- TABLE 127.ELI LILLY AND COMPANY: OPERATING SEGMENTS
- TABLE 128.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
- TABLE 129.ELI LILLY AND COMPANY: NET SALES,
- TABLE 130.ELI LILLY AND COMPANY: KEY STRATERGIES
- TABLE 131.GENTECH HEALTHCARE: COMPANY SNAPSHOT
- TABLE 132.GENTECH HEALTHCARE: OPERATING SEGMENTS
- TABLE 133.GENTECH HEALTHCARE: PRODUCT PORTFOLIO
- TABLE 134.GENTECH HEALTHCARE: NET SALES,
- TABLE 135.GENTECH HEALTHCARE: KEY STRATERGIES
- TABLE 136.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
- TABLE 137.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
- TABLE 138.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
- TABLE 139.GLAXOSMITHKLINE PLC: NET SALES,
- TABLE 140.GLAXOSMITHKLINE PLC: KEY STRATERGIES
- TABLE 141.INTAS PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
- TABLE 142.INTAS PHARMACEUTICALS LIMITED: OPERATING SEGMENTS
- TABLE 143.INTAS PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
- TABLE 144.INTAS PHARMACEUTICALS LIMITED: NET SALES,
- TABLE 145.INTAS PHARMACEUTICALS LIMITED: KEY STRATERGIES
- TABLE 146.NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 147.NOVARTIS AG: OPERATING SEGMENTS
- TABLE 148.NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 149.NOVARTIS AG: NET SALES,
- TABLE 150.NOVARTIS AG: KEY STRATERGIES
- TABLE 151.ORION CORPORATION: COMPANY SNAPSHOT
- TABLE 152.ORION CORPORATION: OPERATING SEGMENTS
- TABLE 153.ORION CORPORATION: PRODUCT PORTFOLIO
- TABLE 154.ORION CORPORATION: NET SALES,
- TABLE 155.ORION CORPORATION: KEY STRATERGIES
- TABLE 156.PFIZER INC.: COMPANY SNAPSHOT
- TABLE 157.PFIZER INC.: OPERATING SEGMENTS
- TABLE 158.PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 159.PFIZER INC.: NET SALES,
- TABLE 160.PFIZER INC.: KEY STRATERGIES
- TABLE 161.SQUARE GROUP: COMPANY SNAPSHOT
- TABLE 162.SQUARE GROUP: OPERATING SEGMENTS
- TABLE 163.SQUARE GROUP: PRODUCT PORTFOLIO
- TABLE 164.SQUARE GROUP: NET SALES,
- TABLE 165.SQUARE GROUP: KEY STRATERGIES
- TABLE 166.SUN PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT
- TABLE 167.SUN PHARMACEUTICAL INDUSTRIES: OPERATING SEGMENTS
- TABLE 168.SUN PHARMACEUTICAL INDUSTRIES: PRODUCT PORTFOLIO
- TABLE 169.SUN PHARMACEUTICAL INDUSTRIES: NET SALES,
- TABLE 170.SUN PHARMACEUTICAL INDUSTRIES: KEY STRATERGIES
- TABLE 171.TEVA PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 172.TEVA PHARMACEUTICALS: OPERATING SEGMENTS
- TABLE 173.TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 174.TEVA PHARMACEUTICALS: NET SALES,
- TABLE 175.TEVA PHARMACEUTICALS: KEY STRATERGIES
- TABLE 176.TORRENT GROUP: COMPANY SNAPSHOT
- TABLE 177.TORRENT GROUP: OPERATING SEGMENTS
- TABLE 178.TORRENT GROUP: PRODUCT PORTFOLIO
- TABLE 179.TORRENT GROUP: NET SALES,
- TABLE 180.TORRENT GROUP: KEY STRATERGIES
- TABLE 181.UCB: COMPANY SNAPSHOT
- TABLE 182.UCB: OPERATING SEGMENTS
- TABLE 183.UCB: PRODUCT PORTFOLIO
- TABLE 184.UCB: NET SALES,
- TABLE 185.UCB: KEY STRATERGIES
- TABLE 186.VIATRIS INC.: COMPANY SNAPSHOT
- TABLE 187.VIATRIS INC.: OPERATING SEGMENTS
- TABLE 188.VIATRIS INC.: PRODUCT PORTFOLIO
- TABLE 189.VIATRIS INC.: NET SALES,
- TABLE 190.VIATRIS INC.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.PARKINSON'S DISEASE DRUGS MARKET SEGMENTATION
- FIGURE 2.PARKINSON'S DISEASE DRUGS MARKET,2021-2031
- FIGURE 3.PARKINSON'S DISEASE DRUGS MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.PARKINSON'S DISEASE DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.PARKINSON'S DISEASE DRUGS MARKET,BY DRUG CLASS,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF DECARBOXYLASE INHIBITORS PARKINSON'S DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF DOPAMINE AGONISTS PARKINSON'S DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF COMT INHIBITORS PARKINSON'S DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF MAO-B INHIBITORS PARKINSON'S DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS PARKINSON'S DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 18.PARKINSON'S DISEASE DRUGS MARKET,BY ROUTE OF ADMINISTRATION,2021(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ORAL PARKINSON'S DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF INJECTION PARKINSON'S DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF TRANSDERMAL PARKINSON'S DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 22.PARKINSON'S DISEASE DRUGS MARKET,BY AGE GROUP,2021(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF 50 OR BELOW 50 PARKINSON'S DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ABOVE 50 YEARS PARKINSON'S DISEASE DRUGS MARKET,2021-2031(%)
- FIGURE 25.PARKINSON'S DISEASE DRUGS MARKET BY REGION,2021
- FIGURE 26.U.S. PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 27.CANADA PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 28.MEXICO PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 29.GERMANY PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 30.FRANCE PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 31.UK PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 32.ITALY PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 33.SPAIN PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 34.REST OF EUROPE PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 35.JAPAN PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 36.CHINA PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 37.INDIA PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 38.AUSTRALIA PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 39.SOUTH KOREA PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 40.REST OF ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 41.BRAZIL PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 42.SAUDI ARABIA PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 43.SOUTH AFRICA PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 44.REST OF LAMEA PARKINSON'S DISEASE DRUGS MARKET,2021-2031($MILLION)
- FIGURE 45. TOP WINNING STRATEGI
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook